Favorable Long-Term Outcome after Liver-Kidney Transplant for Recurrent Hemolytic Uremic Syndrome Associated with a Factor H Mutation — Jeffrey M. Saland (2006) | RDL Network
Favorable Long-Term Outcome after Liver-Kidney Transplant for Recurrent Hemolytic Uremic Syndrome Associated with a Factor H Mutation
Article 2006 en
Authors
JS
Jeffrey M. Saland
SE
Sukru Emre
BS
Benjamin L. Shneider
Abstract
1 min read
A male child initially presented with atypical hemolytic uremic syndrome (HUS) at the age of 4 months and progressed within weeks to end stage renal disease (ESRD). At the age of 2 years he received a live-related kidney transplant from his mother, which, despite initial good function, was lost to recurrent disease after 2 weeks. Complement factor H analysis showed low serum levels and the presence of two mutations on different alleles (c.2918G > A, Cys973Tyr and c.3590T > C, Val1197Ala). His survival on dialysis was at risk because of access failure and recurrent bacteremic episodes. Therefore, at the age of 5 years he received a combined liver-kidney transplant with pre-operative plasma exchange. Initial function of both grafts was excellent and this has been maintained for over 2 years. This report suggests that despite setbacks in previous experience, combined liver-kidney transplantation offers the prospect of a favorable long-term outcome for patients with HUS associated with complement factor H mutations.
Jeffrey M. Saland, Benjamin L. Shneider, Jonathan S. Bromberg, Patricia A. Shi, Stephen C. Ward, Margret S. Magid, Corinne Benchimol, Mouin G. Seikaly, Sukru Emre, Elena Bresin, Giuseppe Remuzzi
Rubén Martínez-Barricarte, Gaia Pianetti, Ruxandra Gautard, Joachim Misselwitz, Lisa Strain, Véronique Frémeaux‐Bacchi, Christine Skerka, Peter F. Zipfel, Tim Goodship, Marina Noris, Giuseppe Remuzzi, Santiago Rodrı́guez de Córdoba
Norberto Perico, Paolo Cravedi, Piero Ruggenenti, Eliana Gotti, Giovanni Rota, Giuseppe Locatelli, Vincenzo Gambara, Annalisa Perna, Stefano Rota, Giuseppe Remuzzi
Discussion(0)
No comments yet. Be the first to comment.